[go: up one dir, main page]

RU94020410A - Method of vomiting treatment or prophylaxis in mammalian and human using the certain quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds - Google Patents

Method of vomiting treatment or prophylaxis in mammalian and human using the certain quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds

Info

Publication number
RU94020410A
RU94020410A RU94020410/14A RU94020410A RU94020410A RU 94020410 A RU94020410 A RU 94020410A RU 94020410/14 A RU94020410/14 A RU 94020410/14A RU 94020410 A RU94020410 A RU 94020410A RU 94020410 A RU94020410 A RU 94020410A
Authority
RU
Russia
Prior art keywords
piperidine
azanorbornane
prophylaxis
related compounds
mammalian
Prior art date
Application number
RU94020410/14A
Other languages
Russian (ru)
Other versions
RU2135179C1 (en
Inventor
К. Десай Мэной
In]
А. Лоуэ Джон III
У. Ватсон Джон
Us]
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU94020410A publication Critical patent/RU94020410A/en
Application granted granted Critical
Publication of RU2135179C1 publication Critical patent/RU2135179C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

FIELD: medicine. SUBSTANCE: method involves the use of the sertain quinuclidine, piperidine, azanorbornane derivatives and related compounds for vomiting treatment or prophylaxis in mammalian including human. EFFECT: enhanced effectiveness.

Claims (1)

Настоящее изобретение относится к способу лечения или профилактики рвоты у млекопитающих, включая человека, с использованием некоторых хинуклидиновых производных, пиперидиновых производных, азанорборнановых производных и родственных им соединений.The present invention relates to a method for treating or preventing vomiting in mammals, including humans, using certain quinuclidine derivatives, piperidine derivatives, azanorbornane derivatives and related compounds.
RU94020410A 1993-06-04 1994-06-03 Method of treatment or prophylaxis of mammals and human with vomiting using some quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds RU2135179C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis
US08/072,629 1993-06-04

Publications (2)

Publication Number Publication Date
RU94020410A true RU94020410A (en) 1996-05-10
RU2135179C1 RU2135179C1 (en) 1999-08-27

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94020410A RU2135179C1 (en) 1993-06-04 1994-06-03 Method of treatment or prophylaxis of mammals and human with vomiting using some quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds

Country Status (19)

Country Link
US (1) US5393762A (en)
EP (1) EP0627221B1 (en)
JP (1) JP2671972B2 (en)
KR (1) KR100190729B1 (en)
CN (1) CN1100535C (en)
AT (1) ATE209490T1 (en)
AU (1) AU666077B2 (en)
CA (1) CA2124990C (en)
DE (1) DE69429208T2 (en)
DK (1) DK0627221T3 (en)
ES (1) ES2164088T3 (en)
HU (1) HU222243B1 (en)
IL (1) IL109802A (en)
MY (1) MY115310A (en)
NZ (1) NZ260674A (en)
PT (1) PT627221E (en)
RU (1) RU2135179C1 (en)
TW (1) TW318791B (en)
ZA (1) ZA943896B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2103269C1 (en) * 1991-05-31 1998-01-27 Пфайзер Инк. Derivatives of chinuclidine or their pharmaceutically acceptable salts and pharmaceutical composition
ES2092113T3 (en) * 1991-06-20 1996-11-16 Pfizer FLUOROALCOXYBENCILAMINE DERIVATIVES OF HETEROCICLES CONTAINING NITROGEN.
EP0533280B2 (en) 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994020500A1 (en) * 1993-03-04 1994-09-15 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DE69617226T2 (en) * 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co., Inc. Piperidine.
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
US6214846B1 (en) * 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
WO2000032192A1 (en) * 1998-11-27 2000-06-08 Takeda Chemical Industries, Ltd. Drugs
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
RU2197961C2 (en) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Agent for nausea and vomiting prophylaxis and arresting
RU2183118C1 (en) * 2001-07-12 2002-06-10 Государственный научный центр РФ Институт медико-биологических проблем РАН Method for preventing vestibulovegetative disorders in human beings under conditions causing sea-sickness
CN1529600A (en) * 2001-07-20 2004-09-15 �Ʒ� Use of NK-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
MXPA06007964A (en) * 2004-01-30 2007-01-26 Pfizer Prod Inc Nk-1 receptor antagonists anesthesia recovery.
PT1713504T (en) * 2004-01-30 2017-08-29 Zoetis Services Llc Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
PT1713801E (en) * 2004-02-02 2008-02-11 Pfizer Prod Inc Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
MX18467A (en) * 1988-11-23 1993-07-01 Pfizer THERAPEUTIC AGENTS OF QUINUCLIDINES
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
DE69105131T2 (en) * 1990-06-01 1995-03-23 Pfizer 3-AMINO-2-ARYLCHINUCLIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
DK0540526T3 (en) * 1990-07-23 1995-04-18 Pfizer quinuclidine derivatives
EP0550635B1 (en) * 1990-09-28 1995-04-19 Pfizer Inc. Fused ring analogs of nitrogen containing nonaromatic heterocycles
JPH0733385B2 (en) * 1991-01-10 1995-04-12 フアイザー・インコーポレイテツド N-alkylquinuclidinium salts as antagonists of substance P
EP0573522B1 (en) * 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
CZ293955B6 (en) * 1991-03-26 2004-08-18 Pfizeráinc Process for preparing substituted piperidine derivatives
AU658898B2 (en) * 1991-05-22 1995-05-04 Pfizer Inc. Substituted 3-aminoquinuclidines
RU2103269C1 (en) * 1991-05-31 1998-01-27 Пфайзер Инк. Derivatives of chinuclidine or their pharmaceutically acceptable salts and pharmaceutical composition
ES2092113T3 (en) * 1991-06-20 1996-11-16 Pfizer FLUOROALCOXYBENCILAMINE DERIVATIVES OF HETEROCICLES CONTAINING NITROGEN.
TW202432B (en) * 1991-06-21 1993-03-21 Pfizer
WO1993006099A1 (en) * 1991-09-16 1993-04-01 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
EP0533280B2 (en) * 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
HUT70741A (en) * 1991-11-12 1995-10-30 Pfizer Acyclic ethylenediamine derivatives as substance p receptor antagonists
JP2656702B2 (en) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 Peptide quinuclidine
EP0641328B1 (en) * 1992-05-18 2001-11-21 Pfizer Inc. Bridged aza-bicyclic derivatives as substance p antagonists
JP2722279B2 (en) * 1992-12-10 1998-03-04 ファイザー・インク． Non-aromatic heterocyclic compounds substituted with aminomethylene and use as antagonists of substance P
WO1994020500A1 (en) * 1993-03-04 1994-09-15 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
WO2000010073A1 (en) * 1998-08-14 2000-02-24 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
IL109802A (en) 2002-04-21
PT627221E (en) 2002-04-29
CN1121806A (en) 1996-05-08
NZ260674A (en) 2000-07-28
IL109802A0 (en) 1994-08-26
DE69429208D1 (en) 2002-01-10
HUT71550A (en) 1995-12-28
EP0627221A2 (en) 1994-12-07
ATE209490T1 (en) 2001-12-15
MY115310A (en) 2003-05-31
ES2164088T3 (en) 2002-02-16
DE69429208T2 (en) 2002-05-23
EP0627221B1 (en) 2001-11-28
AU6452194A (en) 1994-12-15
KR100190729B1 (en) 1999-06-01
EP0627221A3 (en) 1995-08-02
US5393762A (en) 1995-02-28
TW318791B (en) 1997-11-01
RU2135179C1 (en) 1999-08-27
CN1100535C (en) 2003-02-05
HU9401676D0 (en) 1994-09-28
KR950000144A (en) 1995-01-03
DK0627221T3 (en) 2002-02-11
JPH0753362A (en) 1995-02-28
AU666077B2 (en) 1996-01-25
JP2671972B2 (en) 1997-11-05
ZA943896B (en) 1995-12-04
HU222243B1 (en) 2003-05-28
CA2124990C (en) 1999-04-20

Similar Documents

Publication Publication Date Title
RU94020410A (en) Method of vomiting treatment or prophylaxis in mammalian and human using the certain quinuclidine, piperidine, azanorbornane, ethylenediamine derivatives and related compounds
RU94041950A (en) Use of compounds of 3-arylhydroxypropylamine order for enuresis treatment
BG101118A (en) Therapeutical compounds
MY101842A (en) Treatment of oral diseases.
DE3684190D1 (en) USE OF TETRAHYDROBIOPTERINES FOR PRODUCING A MEDICINE FOR TREATING CHILDREN'S AUTISM.
DK0828741T3 (en) Spirocyclic and bicyclic diazinyl and carbazinyloxazolidinones
RU94031102A (en) Sulfides as endotheelin antagonists, and process for treating corresponding diseases
ATE211384T1 (en) USE OF ADENOSINE ANTAGONISTS TO PREVENT AND TREAT PANCREATITIS AND ULCERAS
ATE201597T1 (en) ADMINISTRATION OF RILUZOLE FOR THE TREATMENT OF NEURO-AIDS
RU94002337A (en) Pharmaceutical composition, use of gamma-linolenic acid or dihomo-gamma-linolenic acid for damage treatment after irradiation, treatment method
MD960168A (en) Method for treatment of viral infections and compounds therefor
NO890046L (en) DISUBSTITUTED PYRIDINES.
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
RU94041028A (en) Application of melatonin derivatives for treating desynchronization disorders, pharmaceutical composition
NO982863L (en) New compounds with analgesic effect
ATE222768T1 (en) CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS
ATE204476T1 (en) USE OF 3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZI E TO PRODUCE A MEDICATION FOR THE TREATMENT OF CERTAIN PAIN AND EDEMA
ATE193450T1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE FRACES
ATE193206T1 (en) COMPOSITION FOR TREATING OR PREVENTING HERPES
ATE236633T1 (en) TOPICAL USE OF LOPERAMIDE TO TREAT MICROBIAL INFECTIONS
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
DE59410340D1 (en) Use of bradykinin antagonists to treat viral diseases
ATE178336T1 (en) USE OF A THERAPEUTIC COMPOSITION FOR TREATING BRONCHITIS
UA10928C2 (en) Method for prevention of hypercholesterolemia
ATE254919T1 (en) USE OF PENCICLOVIR TO TREAT HUMAN HERPES VIRUS-8

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090604